An Australian guideline on the diagnosis of overseas acquired Lyme
... localisation of inflammatory foci in the brain. The course is typically chronic progressive and spasticity and cerebellar symptoms are often prominent clinical features. Also on rare occasions cerebral vasculitis, myositis, a dermatomyositis-like syndrome, reactive hyperplasia of the bone marrow, ke ...
... localisation of inflammatory foci in the brain. The course is typically chronic progressive and spasticity and cerebellar symptoms are often prominent clinical features. Also on rare occasions cerebral vasculitis, myositis, a dermatomyositis-like syndrome, reactive hyperplasia of the bone marrow, ke ...
Epidemiology and Risk Analysis Student Guide
... particular adverse event occurs, and taking steps to mitigate that risk and communicate with relevant stakeholders and populations. Epidemiology and risk analysis are both important to the practice of the One Health approach, and professional health science programs incorporate these topics to some ...
... particular adverse event occurs, and taking steps to mitigate that risk and communicate with relevant stakeholders and populations. Epidemiology and risk analysis are both important to the practice of the One Health approach, and professional health science programs incorporate these topics to some ...
Monitoring progression of primary progressive
... are thought to involve a phase in which neurodegenerative changes are developing in the brain but are not yet producing symptoms. In the earliest clinical phase, patients may describe increasingly effortful speech but may be able to perform well on many tests of language function. For some patients, ...
... are thought to involve a phase in which neurodegenerative changes are developing in the brain but are not yet producing symptoms. In the earliest clinical phase, patients may describe increasingly effortful speech but may be able to perform well on many tests of language function. For some patients, ...
Erin Frillarte
... J. Continue care with infectious disease, pulmonary, and rheumatology clinics VI. Conclusion A. Coccidioidomycosis is subclinical in most individuals, with ocular involvement being regarded as rare and usually associated with disseminated disease. B. The diagnosis of intraocular Coccidioidomycosis w ...
... J. Continue care with infectious disease, pulmonary, and rheumatology clinics VI. Conclusion A. Coccidioidomycosis is subclinical in most individuals, with ocular involvement being regarded as rare and usually associated with disseminated disease. B. The diagnosis of intraocular Coccidioidomycosis w ...
Alzheimer's disease
Alzheimer's disease (AD), also known as Alzheimer disease, or just Alzheimer's, accounts for 60% to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually starts slowly and gets worse over time. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD. There are no medications or supplements that decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programs are beneficial with respect to activities of daily living and can potentially improve outcomes. Treatment of behavioral problems or psychosis due to dementia with antipsychotics is common but not usually recommended due to there often being little benefit and an increased risk of early death.In 2010, there were between 21 and 35 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2010, dementia resulted in about 486,000 deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.